New mRNA Vaccine Shows Promise Against Multiple Ebola Viruses
Experimental mRNA vaccine may protect against multiple Ebola viruses
Image: Newscientist
A new mRNA vaccine developed by researchers at the Wuhan Institute of Virology may offer long-term protection against several Ebola viruses, including the Bundibugyo strain currently causing outbreaks in the Democratic Republic of the Congo and Uganda. While the vaccine has shown efficacy in mice, further testing in larger animals and humans is necessary.
- 01The Bundibugyo virus outbreak has infected over 600 people in the Democratic Republic of the Congo and two in Uganda, prompting a public health emergency declaration.
- 02The new vaccine combines mRNA encoding glycoproteins from the Zaire, Sudan, and Bundibugyo viruses within a lipid nanoparticle.
- 03Mice vaccinated with the new mRNA vaccine showed complete protection against Zaire and Sudan viruses, and strong protection against Bundibugyo.
- 04Experts caution that the vaccine's success in rodents does not guarantee efficacy in humans, and non-human primate testing is needed.
- 05The approval process for a multivalent vaccine targeting multiple pathogens is expected to be complex and lengthy.
Advertisement
In-Article Ad
Researchers at the Wuhan Institute of Virology in China have developed a promising mRNA vaccine that may provide long-term protection against multiple Ebola viruses, including the Bundibugyo strain, which is currently causing outbreaks in the Democratic Republic of the Congo and Uganda. The World Health Organization has declared this outbreak a public health emergency, with over 600 infections reported. Unlike the Zaire virus, which has two approved vaccines, there are currently no vaccines for Bundibugyo or Sudan viruses. The new vaccine combines mRNA encoding glycoproteins from all three viruses within a lipid nanoparticle, allowing for a broad-spectrum immune response. In trials, vaccinated mice demonstrated complete protection against Zaire and Sudan viruses, and strong protection against Bundibugyo. However, researchers emphasize that these results are preliminary and further testing in larger animals and humans is required. Experts caution that the path to approval for a multivalent vaccine is complex, highlighting the need for additional safety and efficacy studies before clinical use can be considered.
Advertisement
In-Article Ad
The development of this vaccine could significantly enhance public health responses to Ebola outbreaks in affected regions.
Advertisement
In-Article Ad
Reader Poll
Do you support the development of multivalent vaccines for infectious diseases?
Connecting to poll...
More about World Health Organization
Read the original article
Visit the source for the complete story.